- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
11 The Relationship of Diabetic Retinopathy and Glaucoma |
329 |
|
|
prevalence of 3.8%.84 This percentage is probably still higher than the true value as it derived from a tertiary referral clinic and was not population based.84 In the DRS, 2.3% of eyes with PDR had NVI by clinical examination.85 A higher percentage of cases of NVI are bilateral in association with diabetic retinopathy than other causes of NVI, reflecting the generally symmetric nature of diabetic retinopathy.79 Bilateral involvement of NVI in association with diabetic retinopathy has been reported in 5–76%.74 NVI occasionally spon-
taneously resolves clinically, although histological evidence of the vessels may be detected.74,86,87
11.4 Clinical Detection
Iris neovascularization usually follows the development of proliferative diabetic retinopathy, but cases
have been described in which NVI was seen in the absence of PDR.83,88,89 In these cases, however,
severe nonproliferative retinopathy was present or intracapsular cataract extraction had been performed.83,89 Studies have reported widespread
areas of peripheral retinal capillary nonperfusion in eyes with PDR and in eyes with NVI.62,63 There
is a controversy regarding the sequence of anterior segment neovascularization.
Why the Difference in Sequence of Ocular Neovascularization in Different Diseases?
We have noted that in diabetic retinopathy, retinal neovascularization typically precedes iris and angle neovascularization and that typically pupillary margin neovascularization precedes angle neovascularization.90 Why, then, in ischemic central retinal vein occlusion, is retinal neovascularization rare, but anterior segment neovascularization common, and why is it much more common in central retinal vein occlusion to find NVA before pupillary margin NVI?91 And why, in retinoblastoma, is NVI present in 44–80% of cases, yet retinal neovascularization absent?92,93 Henkind93 hypothesized that the iris vessels are more sensitive to a diffusible factor, not known at the time, but now known to be VEGF. This seems too simple an explanation, as there is no evidence in the experimental models that iris vessels have greater sensitivity than retinal vessels to neovascularization to intravitreal injections of VEGF, and the gradient of VEGF is decreasing from vitreous to aqueous. Although VEGF is upregulated in necrotic retinoblastoma cells and in outer nuclear layer cells in adjacent areas of detached retina, it is possible that other molecules than VEGF contribute to NVI in cases of retinoblastoma.92 Intraocular fluid samples have not been available to sample in this condition. In central retinal vein occlusion, the ischemic retina may have insufficient viability to respond to VEGF with neovascularization, in contrast to the iris vessels.
Most authors report that in diabetic patients pupillary margin iris neovascularization consistently precedes angle neovascularization, pathological evidence exists to support this sequence, and
some classification schemes are based on this pre-
sumption.59,75,79,83,87,90,74,94,80,95 In five clinical ser-
ies comprising 245 eyes, no case of NVA was seen without concomitant NVI.59,83,86,96,80 Based on
Hanley’s rule of three, we can be 95% confident
that the probability of NVA without NVI is at most 3/245 (1.2%).96,97 However, rare cases have
been reported in which angle new vessels were seen in the absence of pupillary margin new vessels.63,98
The authors consider the general clinical rule to be true, conceding that rare counterexamples may exist, and we have illustrated our understanding of the clinical sequence of anterior segment neovascularization in association with diabetic retinopathy based on this understanding (Fig. 11.4).
Unlike the situation with diabetic retinopathy, NVA is often found before pupillary margin NVI in central retinal vein occlusion, occurring in 12% of cases developing anterior segment neovascularization.91 If it can occur in diabetic retinopathy, the frequency of its occurrence is much less, and there seems to be little reason to do undilated
330 |
D.J. Browning and M.H. Rotberg |
|
|
Fig. 11.4 Diagram illustrating the natural history of uninhibited anterior segment neovascularization associated with diabetic retinopathy. A – new vessels begin at the pupillary margin. B – next new vessels can appear in the angle. C – next the iris stroma is involved with new vessels and angle
synechiae develop. D – pupillary margin posterior synechia to the lens capsule develop and iris bombe may occur. E – hyphema may occur when iris neovascularization
bleeds. Adapted from and reproduced with permission from Roth and Brown172
gonioscopy in search of NVA in diabetic eyes with no pupillary margin NVI.99 NVI in association with diabetic retinopathy behaves differently from NVI in association with central retinal vein occlusion. In the latter, the course of NVI is compressed and neovascular glaucoma can occur
rapidly, whereas on an average the course is slower in the case of diabetic retinopathy.88,100 This gen-
eral observation may reflect the generally lower levels of intraocular VEGF seen in diabetic retinopathy compared with ischemic central retinal vein occlusion.
Actual Practice Patterns for Undilated Slit Lamp Examination in Patients with Diabetic Retinopathy
Preferred practice patterns are published by the American Academy of Ophthalmology ‘‘to identify characteristics and components of quality eye care.’’101 It is of interest, therefore, to know if the intent of these patterns is being met in actual practice. An undilated slit lamp examination is considered part of the preferred practice, in part to detect NVI in patients with diabetic retinopathy. Regarding undilated slit lamp examination to check for NVI in diabetic patients, one of the authors (DJB) performed a survey in North Carolina to estimate congruence between preferred and actual practice patterns. Of 369 ophthalmologists polled, 335 (91%) responded. Forty-one percent of ophthalmologists report omitting undilated slit lamp examination in at least 25% of patients. Of the 138 ophthalmologists in this group, when asked if they modify their practice if they know the patient has had diabetes for at least 10 years, 44 (32%) responded that they do not. A potential
11 The Relationship of Diabetic Retinopathy and Glaucoma |
331 |
|
|
problem exists in omitting undilated examination of the iris in patients with long duration of diabetes. It is likely that detection of NVI is impaired by dilation. An example is shown in Figs. 11.5 and 11.6.
Fig. 11.5 In the undilated state, NVI is shown (arrowhead) Fig. 11.6 In the dilated state, the NVI cannot be detected
Clinical detection of NVI is clouded by the difficulty of distinguishing dilated normal iris vessels from NVI. Eyes with inflammation can have dilated iris vessels that may masquerade as NVI. Iris neovascularization must also be distinguished from iris vascular tufts, which are located along the pupillary
margin and do not occur on the surface of the iris stroma or in the angle.90,102
Iris color influences the ease of detection of NVI.79 Clinical detection at the slit lamp is easier in a lightcolored iris.74 Subtle NVI may be difficult to discern in a dark-colored iris. Red-free light may make detection of the red NVI easier.103 In difficult cases, iris fluor-
escein angiography and gonioangiography can make detection of NVI and NVA easier.62,80 Iris fluorescein
angiography is more sensitive than slit lamp biomicro-
scopy in the detection of NVI and NVA, but is also less specific.80,104,105 Dilated iris vessels in eyes with
iritis, normal iris vessels in older patients, and eyes of diabetics with retinopathy but no NVI can leak fluorescein on angiography just as does NVI, thus iris
fluorescein angiography is not always a reliable method for distinguishing the two conditions.59,106–108
Iris fluorangiography is an often forgotten method of assessing the presence of diabetic retinopathy in eyes with dense cataracts before proceeding to surgery. Presence of NVI implies that severe NPDR or worse is present and allows for preoperative planning such
as use of intravitreal bevacizumab or early postoperative PRP.83 Indocyanine green iris angiography has also been investigated in patients with diabetic retinopathy and is not as useful as iris fluorescein angiograms.109
Figures 11.7, 11.8, and 11.9 show standards useful in interpreting iris fluorescein angiograms.
Fig. 11.7 Example of a normal iris fluorescein angiogram. No dye leakage is present, although in patients over the age of 50 years, a small amount of pupillary margin leakage of fluorescein can be considered normal. Reprinted with permission from Bandello et al.83
332 |
D.J. Browning and M.H. Rotberg |
|
|
Fig. 11.8 Example of nonproliferative diabetic iridopathy. Dye leakage is prominent in the late phase but neovascularization is absent. Reprinted with permission from Bandello et al.83
provide a prognosis for visual outcome and to allow correlations to be made with stages of diabetic retinopathy.88,80 They differ not only in conception, but in the method used for detecting NVI and NVA. Although standardized classifications have attraction in common conditions such as diabetic retinopathy, the relative uncommonness of NVI makes the ability to recall details of any system difficult for the clinician, and we favor a method of straightforward description of pupillary margin and angle involvement by neovascularization as being most practical (Tables 11.1 and 11.2).
11.6Risk Factors for Iris Neovascularization
Fig. 11.9 Example of iris neovascularization present around the entire pupillary margin and at several places on the iris stroma. Reprinted with permission from Bandello et al.83
11.5 Classification
Several classification schemes for NVI and NVA
have been proposed and none is accepted by the majority of clinicians.62,83,88,110 There are also dif-
ferent classification schemes for the clinical and histopathological stages of NVA (Fig. 11.10).82,111,112
The purpose of these schemes is to attempt to
Several risk factors for NVI relate to characteristics of diabetic retinopathy severity and fluorescein angiography. Hamanaka and colleagues performed nearly simultaneous goniofluorescein angiography and panoramic fundus fluorescein angiography in a series of eyes with proliferative diabetic retinopathy.62 They graded eyes as having any capillary nonperfusion in the temporal raphe and radial peripapillary capillary network regions and graded whether midperipheral retinal capillary nonperfusion exceeded 50% or not. Figure 11.11 illustrates these regions. Presence of disk neovascularization (NVD) was also noted. They then correlated the presence of NVA with the findings on fundus fluorescein angiography and the status of NVD. The strongest risk factor for the presence of NVA was midperipheral capillary nonperfusion greater than 50% by area with a relative risk of 16.7 compared to eyes without this characteristic (Table 11.3). The relative risk is much higher for this factor because of the rarity of finding an eye with NVA when capillary nonperfusion of the midperiphery falls below 50%. Only 1 out of 28 such eyes had NVA.
Risk factors for development of NVI in eyes with diabetic retinopathy include previous vitrectomy and previous cataract extraction, both of which
remove a diffusion barrier for VEGF access to the aqueous humor.89,115 Attempts to predict post-
operative NVI after vitrectomy by using preoperative iris fluorescein angiography have not been successful. Aphakia has been reported to be a risk factor for NVI in eyes with diabetic retinopathy in
11 The Relationship of Diabetic Retinopathy and Glaucoma |
333 |
|
|
Fig. 11.10 Classification of NVA from Ohnishi et al. using fluorescein gonioangiography for detection. In grade 1, dot proliferations are seen at the iris root. In grade 2, a linear vessel arising from these dot proliferations rises at a perpendicular to the iris root to connect to the trabecular meshwork. In grade 3, an arborization of the vessel over the surface of the trabecular meshwork is seen. In grade 4, contracture of the neofibromyovascularization occurs with synechia. Reprinted with permission from Ohnishi et al.80
the past, but is rarely encountered in recent years because almost all eyes receive intraocular lens implants.89,115 Posterior pseudophakia is probably not a risk factor for NVI, although anterior pseudophakia may be.116 Silicone oil present in the vitreous cavity can reduce the risk of NVI in such cases, but not eliminate it.117 Rhegmatogenous or peripheral tractional retinal detachment in an eye with diabetic
retinopathy increases the risk of NVI, and repair of such detachments can lead to NVI regression.68,118
Neodymium-YAG capsulotomy after extracapsular cataract extraction is a potential risk factor for anterior segment neovascularization.119
In eyes with diabetic retinopathy undergoing vitrectomy, the risk factors for postoperative development of rubeosis are intraoperative lensectomy, increased preoperative retinopathy severity, and absence of preoperative PRP associated with relative risks of 3.3 (95% CI 2.0, 5.4), 2.1 (95% CI 1.3, 3.4), and 1.7 (95% CI 1.1, 2.6), respectively.68 If an eye undergoing vitrectomy has preoperative NVI, the odds are increased that it will have postoperative NVI.95 In these cases, presence of a postoperative retinal
detachment negatively affects regression of NVI.95
Table 11.1 Iris neovascularization grading systems
|
|
Grades |
|
|
|
Reference |
Detection method |
0 |
1 |
2 |
3 |
|
|
|
|
|
|
Teich 88, |
Slit lamp |
Pupillary margin |
Pupillary margin |
Ciliary zone NVI or |
Ciliary zone NVI or |
Weiss113 |
biomicroscopy |
NVI <2 |
NVI >2 |
ectropion uvea of |
ectropion uvea of |
|
|
quadrants |
quadrants |
1–3 quadrants |
4 quadrants |
Bandello83 |
Iris FA |
No fluorescein |
Dilated iris |
Pupillary margin or |
New vessels in the |
|
|
leakage |
capillaries that |
stromal new |
angle with |
|
|
|
leak fluorescein |
vessels that leak |
elevated IOP |
|
|
|
|
fluorescein |
|
Tauber |
Slit lamp |
1 quadrant involved; |
2 quadrants |
3 quadrants |
4 quadrants |
et al.110 |
biomicroscopy |
pupillary margin, |
involved; |
involved; |
involved; |
|
and |
iris stroma, and |
pupillary margin, |
pupillary margin, |
pupillary margin, |
|
gonioscopy |
angle |
iris stroma, and |
iris stroma, and |
iris stroma, and |
|
|
involvement |
angle |
angle |
angle |
|
|
graded |
involvement |
involvement |
involvement |
|
|
|
graded |
graded |
graded |
|
|
|
|
|
|
Not all the grading systems use the same numbering. Some start at zero and some start at 1. For comparison purposes, they have all been converted into a scale starting at zero. Ciliary zone – the outer zone of the iris separated from the pupillary zone by the collarette.
